Key points are not available for this paper at this time.
OBJECTIVE: This is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain. DESIGN: A case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects. SETTING: An outpatient pain management center located within a major university medical center. PATIENTS: Convenience sample of patients referred for management of intractable neuropathic pain. INTERVENTIONS: Simplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses. MAIN OUTCOME MEASURES: Patient self-reports and pain scores in successive office visits. RESULTS: Gabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.
Rosner et al. (Fri,) studied this question.